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Chlamydia pneumoniae is an obligate intra-
cellular parasite which infects mucosal 
surfaces of the human respiratory tract 
causing sinusitis, pharyngitis, bronchitis, 
and pneumonia. Although the bacterium 
causes acute disease, mildly symptomatic, 
asymptomatic, or unrecognized infec-
tions are most common (Kuo et al., 1995). 
C. pneumoniae infections are widespread 
among children 5–14 years of age and by 
age 20 years about 50% of young adults have 
detectable antibodies to the microorganism. 
The seroprevalence to C. pneumoniae con-
tinues to rise in the population and reaches 
approximately 75% in the elderly. Moreover, 
the epidemiological data suggests that most 
people are infected and re-infected through-
out life (Kuo et al., 1995). C. pneumoniae 
was established as a human respiratory 
pathogen in 1986 (Grayston et al., 1986) and 
initially research on this pathogen was rig-
orous, especially due to its association with 
variety of chronic diseases such as Reiter’s 
syndrome, sarcoidosis, asthma, chronic 
obstructive pulmonary disease (COPD), 
multiple sclerosis, Alzheimer disease, and 
atherosclerosis. However in recent years, the 
interest in basic as well as clinical research 
on C. pneumoniae has undergone a sharp 
decline. One of the major factors that could 
have contributed to this decline may include 
frequent discrepancies in published data. 
Multiple studies have described the pres-
ence of C. pneumoniae in patient samples 
from those who suffered from the chronic 
diseases listed above by either serology, 
polymerase chain reaction (PCR), RT-PCR, 
immunocytochemistry (ICC) or electron 
microscopy, and occasionally even by direct 
isolation of the bacterium. Conversely, there 
are laboratories which could not confirm 
these findings. Inter-laboratory varia-
tions in sample collection, processing and 
C. pneumoniae detection methods are likely 
to be responsible for these inconsistencies 
(reviewed in Boman and Hammerschlag, 
2002). However, numerous studies pub-
lished on C. pneumoniae, describing the 
presence or absence of the microorgan-
ism, often lacked appropriate positive and/
or negative controls. Using only one or 
two methods for C. pneumoniae detection 
in clinical specimens is insufficient and 
may have led to inaccurate conclusions 
(Puolakkainen et al., 1996; Mills et al., 1998; 
Sriram et al., 1998; Fainardi et al., 2008). 
Furthermore, positive labeling of cells or tis-
sue for C. pneumoniae antigen(s) with an 
antibody does not necessarily represent an 
intact bacterium. It has been demonstrated 
that chlamydiae-infected cells stay positive 
for several of the chlamydial antigens, for 
example LPS, weeks after the bacterium has 
been degraded by lysosomes (Wolf et al., 
2005). Direct isolation of C. pneumoniae 
from a patient’s sample still represents 
the most conclusive, yet the most difficult 
method of detection of this pathogen. In 
spite of these inconsistencies there may also 
be another aspect which could have contrib-
uted to the current discrepancies existing 
in the C. pneumoniae field. As mentioned 
above, the bacterium frequently causes mild 
or asymptomatic infections, which often 
remain unrecognized and consequently 
untreated. In cases such as these, it cannot 
be conclusively determined at what point 
during their lifetime the studied patients 
actually suffered from an acute C. pneu-
moniae infection or re-infection. Many 
of these concerns could hypothetically be 
addressed by serology. According to the 
CDC standards for diagnostic detection of 
C. pneumoniae in clinical samples by micro-
immuno-fluorescence (MIF), fourfold rise 
in IgG titer or an IgM titer ≥16 indicates 
an acute infection and an IgG titer of ≥16 
suggests past exposure to the microorgan-
ism. Elevated IgA was excluded as a valid 
indicator of persistent or chronic infec-
tion (Dowell et al., 2001). Unfortunately, 
the MIF, which is considered the “gold 
standard” for detection of C. pneumoniae 
in humans does not seem to be absolutely 
reliable either. Cases of acute, culture-
positive C. pneumoniae illness without 
seroconversion have been reported (Kutlin 
et al., 1998; Hammerschlag and Roblin, 
2000). Conversely, the presence of an acute 
infection detected by MIF has been discov-
ered among subjectively healthy individuals 
(Hyman et al., 1995). Thus, it is likely that 
the outcome of C. pneumoniae infection 
depends on the infectious dose and more 
importantly on fitness of the immune sys-
tem of each individual. Numerous research-
ers tend to link various chronic diseases to 
so called chlamydial persistence. However, 
very little is known about the actual pathol-
ogy caused to tissues and/or organs by pro-
ductive C. pneumoniae infection in humans. 
This considerable lack of basic knowledge 
concerning the pathogen and its effects on 
the human body has led many studies to 
questionable conclusions.
One example of this is represented by 
reports on secondary prevention of coro-
nary heart disease by treatment of patients 
who suffered from myocardial infarction 
with azithromycin (O’Connor et al., 2003; 
Grayston et al., 2005). In view of the fact that 
cardiovascular disease is one of the leading 
causes of fatalities in the developed world, 
it is not surprising that an association of 
C. pneumoniae with atherosclerosis was a 
priority to investigate. Participants enrolled 
in these studies, were largely represented by 
the older population, who had previously 
suffered from myocardial infarction and 
had a C. pneumoniae titer of IgG 1:16 or 
more, indicative of past infection. No data 
concerning the presence of acute sera was 
provided (Dunne, 2000; O’Connor et al., 
2003; Grayston et al., 2005). The fact that 
an active C. pneumoniae infection was not 
established in this group of patients is a 
critical issue. Unfortunately, no validated 
serological marker for persistent or chronic 
C. pneumoniae infection is currently avail-
able (Dowell et al., 2001) and it is highly 
likely that most of these participants were 
infected or re-infected with the microor-
ganism in the past, long before they received 
azithromycin. These studies clearly demon-
strated that treatment of patients who had 
suffered from cardiovascular disease with 
azithromycin did not reduce or alter the risk 
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of recurrence of cardiac events. However, 
they completely failed to address the role, if 
any, of C. pneumoniae in the course of car-
diovascular disease (O’Connor et al., 2003; 
Grayston et al., 2005). An atherosclerotic 
lesion takes many years to develop during 
which the patient could have encountered 
asymptomatic C. pneumoniae infection(s) 
at any time. If the bacterium does contrib-
ute to various chronic diseases one must not 
disregard the possibility that an injury to the 
arteries and other parts of our body may 
be achieved during the course of an acute 
respiratory infection with C. pneumoniae. If 
the microorganism is ever shown to cause or 
worsen any of the proposed chronic diseases, 
research on this pathogen must first prop-
erly investigate primary infection within 
the human respiratory tract. Similarly to C. 
trachomatis, infections with C. pneumoniae 
are often asymptomatic meaning that the 
infected person is unlikely to receive proper 
antibiotic treatment. Therefore clearance of 
the pathogen must entirely depend on the 
immune response of the host. It still remains 
unclear whether any of the diseases, respira-
tory or non-respiratory, linked to C. pneu-
moniae are caused directly by chlamydial 
growth or by the immune system’s attempt 
to resolve the infection or both. The recent 
body of evidence suggests that C. pneumo-
niae employs sophisticated, species-specific 
strategies, which are comparatively more 
efficient than those utilized by C. tracho-
matis, in order to avoid recognition by the 
host innate immune system (Wolf et al., 
2009 and unpublished data).
Although all chlamydiae share similari-
ties in biology, they also display extraordi-
nary diversity in tissue tropism and disease 
manifestation. Based on comparisons 
among sequenced chlamydial genomes, 
it seems that C. pneumoniae represents an 
intriguing chlamydial species with unique 
features, all of which are worthy of further 
investigation. For example, the C. pneu-
moniae chromosome contains a plasticity 
zone, a region with a higher rate of DNA 
reorganization, which is three times larger 
than the plasticity zone of C. trachomatis 
(∼160 versus ∼50 kb, respectively; Read 
et al., 2000). It is postulated that the gene 
content within the plasticity zone signifi-
cantly contributes to the virulence of each 
chlamydial species. Moreover, C. pneu-
moniae contains 21 pmp genes encoding 
chlamydial polymorphic membrane pro-
teins compared to only nine detected in 
C. trachomatis. Overall, the C. pneumoniae 
genome is ∼0.15 Mb larger than that of 
C. trachomatis and contains 214 coding 
sequences which are not found in C. tra-
chomatis (Kalman et al., 1999). C. pneu-
moniae is an established pathogen causing 
a significant number of respiratory infec-
tions in humans. However, at this point 
there is insufficient data with regard to 
the basic biology of this microorganism 
that would help to elucidate pathogenic 
strategies employed by C. pneumoniae in 
order to achieve successful invasion of its 
human host. In conclusion, more rigorous 
and thorough research on C. pneumoniae is 
absolutely essential for better understand-
ing of its virulence within the human res-
piratory tract and its potential association 
with various chronic diseases.
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